肉瘤样肝细胞癌患者的临床表现与结局
基于台湾大学医院癌症登记数据库(1996-2016年)5,047例组织学确诊肝细胞癌患者,识别出40例肉瘤样肝细胞癌,并按性别、年龄和巴塞罗那临床肝癌分期进行倾向性评分匹配纳入160例非肉瘤样肝细胞癌患者。肉瘤样肝细胞癌患者中仅47.5%呈现典型肝细胞癌影像模式,病理分级更晚期,中位无复发生存期(13.3 vs. 84.2个月)和中位总生存期(8.3 vs. 69.3个月)均显著短于非肉瘤样组。多变量Cox比例风险模型显示组织学肉瘤样子型是全因死亡(HR 6.47,95%CI 3.12-13.43,P<0.0001)和肿瘤复发(HR 4.08,95%CI 1.72-9.66,P=0.001)的独立预测因子。
要点
- 肉瘤样肝细胞癌患者中仅47.5%呈现典型肝细胞癌影像模式。
- 肉瘤样肝细胞癌病理分级更晚期(III和IV级:42.5% vs. 23.8%,P<0.0001)。
- 组织学肉瘤样子型是全因死亡和肿瘤复发的独立预测因子。
核心结论
- 与非肉瘤样肝细胞癌相比,肉瘤样肝细胞癌与更晚期的组织学分级和非典型影像模式相关。
- 组织学肉瘤样子型是肝细胞癌患者根治性治疗后肿瘤复发和全因死亡的独立预测因子。
研究设计与样本
- 从台湾大学医院癌症登记数据库(1996-2016年)识别5,047例组织学确诊肝细胞癌患者,其中40例肉瘤样肝细胞癌来自该院病理数据库。
- 通过倾向性评分匹配按性别、年龄和巴塞罗那临床肝癌分期纳入160例非肉瘤样肝细胞癌患者。
主要发现
- 肉瘤样肝细胞癌患者大多数为男性(75%),中位年龄58岁。
- 仅47.5%的肉瘤样肝细胞癌患者呈现典型肝细胞癌影像模式。
- 肉瘤样肝细胞癌病理分级较非肉瘤样肝细胞癌更晚期(III和IV级:42.5% vs. 23.8%,P<0.0001)。
- 肉瘤样组中位无复发生存期显著短于非肉瘤样组(13.3 vs. 84.2个月,log-rank P<0.0001)。
- 肉瘤样组中位总生存期显著短于非肉瘤样组(8.3 vs. 69.3个月,log-rank P<0.0001)。
关键数值与推荐
- 多变量Cox比例风险模型显示组织学肉瘤样子型是全因死亡的独立因素(HR 6.47,95%CI 3.12-13.43,P<0.0001)。
- 多变量Cox比例风险模型显示组织学肉瘤样子型是肿瘤复发的独立因素(HR 4.08,95%CI 1.72-9.66,P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. Sarcomatoid HCC is a rare histological subtype of HCC with largely unclear clinical manifestations and outcomes. We evaluated the clinical manifestations and outcomes of patients with sarcomatoid HCC. We identified 5,047 patients with histologically proven HCC from the Cancer Registry Database (1996-2016) of National Taiwan University Hospital. Among them, 40 patients with sarcomatoid HCC were identified from the pathology database of National Taiwan University Hospital. We included 160 patients with nonsarcomatoid HCC through propensity score matching according to sex, age, and Barcelona Clinic Liver Cancer stage. The majority of these patients with sarcomatoid HCC were men (75%); their median age was 58 years. Only 47.5% of the patients with sarcomatoid HCC presented with typical image patterns of HCC. The pathological grading of sarcomatoid HCC was more advanced compared with that of nonsarcomatoid HCC (42.5% vs. 23.8% in grade III and IV, P < 0.0001). The sarcomatoid group had significantly shorter median recurrence-free (13.3 vs. 84.2 months, log-rank P < 0.0001) and overall (8.3 vs. 69.3 months, log-rank P < 0.0001) survival than did the nonsarcomatoid group. The results of the multivariable Cox proportional hazard model revealed histological sarcomatoid subtype as an independent factor for all-cause mortality (hazard ratio [HR], 6.47; 95% confidence interval [CI], 3.12-13.43; P < 0.0001) and tumor recurrence (HR, 4.08; 95% CI, 1.72-9.66; P = 0.001). Conclusion: Compared with nonsarcomatoid HCC, sarcomatoid HCC was associated with more advanced histological grades and atypical image patterns. Histological sarcomatoid subtype is an independent predictor of tumor recurrence after curative treatment and all-cause mortality in patients with HCC.
引用
- Liao SH, Su TH, Jeng YM, et al. Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. Hepatology. 2019. PMID: 30014620. doi:10.1002/hep.30162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。